Disagreement between drug effects on autonomic function and mortality: another unreliable surrogate endpoint in heart failure?
- 1 September 2000
- journal article
- editorial
- Published by Elsevier in International Journal of Cardiology
- Vol. 75 (2-3) , 176-177
- https://doi.org/10.1016/s0167-5273(00)00318-1
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failureInternational Journal of Cardiology, 2000
- Effect of mibefradil on heart rate variability in patients with chronic heart failureInternational Journal of Cardiology, 2000
- Effect of Mibefradil, a T-Type Calcium Channel Blocker, on Morbidity and Mortality in Moderate to Severe Congestive Heart FailureCirculation, 2000
- Heart failure 99 — the Moxcon storyInternational Journal of Cardiology, 1999
- 15 years of heart-failure trials: what have we learned?The Lancet, 1998
- Can drug effects on mortality in heart failure be predicted by any surrogate measure?European Heart Journal, 1997
- Randomised study of effect of ibopamine on survival in patients with advanced severe heart failureThe Lancet, 1997
- Heart rate variability in left ventricular dysfunction and heart failure: effects and implications of drug treatment.Heart, 1994
- Role of surrogate end points in the evaluation of drugs for heart failureJournal of the American College of Cardiology, 1993
- Effects of long-term therapy with oral ibopamine on resting hemodynamics and exercise capacity in patients with heart failure: relationship to the generation of N-methyldopamine and to plasma norepinephrine levels.Circulation, 1986